The Beneficial Effects of QIAPI 1® against Pentavalent Arsenic-InducedLung Toxicity: A Hypothetical Model for SARS CoV2-I nduced LungToxicity / Arturo Solís Herrera, Narasimha M. Beeraka, Mikhail Y. Sinelnikov, Vladimir N. Nikolenko, Dimitry B. Giller, Luis Fernando Torres Solis, Liudmila M. Mikhaleva, Siva G. Somasundaram, Cecil E. Kirkland, Gjumrakch Aliev
Abstract: Exposure to environmental toxicants such as Arsenic (As) can result in As-induced alterationsin immune regulators. Consequently, people who are more prone to viral infections like influenza A orB, H1N1, SARS CoV (Severe Acute Respiratory Syndrome Coronavirus), and SARS CoV2 may developa susceptibility to immune responses in their lungs because our previous reports delineated the abilityof QIAPI 1 ® , a melanin precursor, to dissociate water molecules with simultaneous therapeutic efficacyagainst central nervous system (CNS) diseases, retinopathy, and As-induced renal toxicity. Consideringthe commonalities of lung pathology of SARS CoV and As-induced toxicity, the aim of this study is todecipher the efficacy of QIAPI 1 ® against pentavalent As-induced lung toxicity by examining the pulmonarypathology. Hematoxylin & Eosin (H&E) staining was used for ascertaining the lung pathologyin Wistar rat models. Animals were divided into 3 groups: control group, group treated with pentavalentAs, and a group treated with pentavalent As and QIAPI 1 ® . There were no significant changes in lunghistopathology in the control group as indicated by intact morphology. The As-treated group revealeddamage to the histoarchitecture with pulmonary edema, interstitial fibrosis, diffuse alveolar damage, Bronchiolitis obliterans organizing pneumonia (BOOP)-lesions, formation of hyaline membrane, multinucleatedgiant pneumocytes, atypical pneumocytes, inflammatory cell infiltration, and interstitial edema.The group treated with As and QIAPI 1 ® significantly associated with mitigated histological signs oflung inflammation induced by Arsenic. Therefore, QIAPI 1 ® can be recommended as antagonistic to Asinducedlung toxicity. In conclusion, this model could be preferred as a hypothetical model to examinethe efficacy of QIAPI 1 ® in SARS CoV2-induced pulmonary damage. Future studies are warranted todelineate the efficacy of QIAPI 1® against SARS CoV and SARS CoV2 lung pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - 23(2022), 2, Seite 9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herrera, Arturo Solís [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (9 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011171677 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011171677 | ||
| 003 | DE-627 | ||
| 005 | 20231128145621.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011171677 | ||
| 035 | |a (KFL)prod_DARH_.E451D9858A3F10DAF1B49779FBCE2FB1F0724E8A | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Herrera, Arturo Solís |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Beneficial Effects of QIAPI 1® against Pentavalent Arsenic-InducedLung Toxicity: A Hypothetical Model for SARS CoV2-I nduced LungToxicity |c Arturo Solís Herrera, Narasimha M. Beeraka, Mikhail Y. Sinelnikov, Vladimir N. Nikolenko, Dimitry B. Giller, Luis Fernando Torres Solis, Liudmila M. Mikhaleva, Siva G. Somasundaram, Cecil E. Kirkland, Gjumrakch Aliev |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (9 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract: Exposure to environmental toxicants such as Arsenic (As) can result in As-induced alterationsin immune regulators. Consequently, people who are more prone to viral infections like influenza A orB, H1N1, SARS CoV (Severe Acute Respiratory Syndrome Coronavirus), and SARS CoV2 may developa susceptibility to immune responses in their lungs because our previous reports delineated the abilityof QIAPI 1 ® , a melanin precursor, to dissociate water molecules with simultaneous therapeutic efficacyagainst central nervous system (CNS) diseases, retinopathy, and As-induced renal toxicity. Consideringthe commonalities of lung pathology of SARS CoV and As-induced toxicity, the aim of this study is todecipher the efficacy of QIAPI 1 ® against pentavalent As-induced lung toxicity by examining the pulmonarypathology. Hematoxylin & Eosin (H&E) staining was used for ascertaining the lung pathologyin Wistar rat models. Animals were divided into 3 groups: control group, group treated with pentavalentAs, and a group treated with pentavalent As and QIAPI 1 ® . There were no significant changes in lunghistopathology in the control group as indicated by intact morphology. The As-treated group revealeddamage to the histoarchitecture with pulmonary edema, interstitial fibrosis, diffuse alveolar damage, Bronchiolitis obliterans organizing pneumonia (BOOP)-lesions, formation of hyaline membrane, multinucleatedgiant pneumocytes, atypical pneumocytes, inflammatory cell infiltration, and interstitial edema.The group treated with As and QIAPI 1 ® significantly associated with mitigated histological signs oflung inflammation induced by Arsenic. Therefore, QIAPI 1 ® can be recommended as antagonistic to Asinducedlung toxicity. In conclusion, this model could be preferred as a hypothetical model to examinethe efficacy of QIAPI 1 ® in SARS CoV2-induced pulmonary damage. Future studies are warranted todelineate the efficacy of QIAPI 1® against SARS CoV and SARS CoV2 lung pathology | ||
| 700 | 1 | |a Beeraka, Narasimha M. |e verfasserin |4 aut | |
| 700 | 1 | |a Sinelnikov, Mikhail Y. |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolenko, Vladimir N. |e verfasserin |4 aut | |
| 700 | 1 | |a Giller, Dimitry B. |e verfasserin |4 aut | |
| 700 | 1 | |a Solis, Luis Fernando Torres |e verfasserin |4 aut | |
| 700 | 1 | |a Mikhaleva, Liudmila M. |e verfasserin |4 aut | |
| 700 | 1 | |a Somasundaram, Siva G. |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkland, Cecil E. |e verfasserin |4 aut | |
| 700 | 1 | |a Aliev, Gjumrakch |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d Hilversum : Bentham Science Publ., 2000 |g 23(2022), 2, Seite 9 |h Online-Ressource |w (DE-627)KFL00000636X |w (DE-600)2044611-1 |w (DE-576)273880926 |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:2 |g pages:9 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-2010&volume=23&issue=2&spage=307 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 2 |h 9 | ||